Income Statement

v3.10.0.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Revenue:        
Grant and licensing revenue $ 1,143,177 $ 411,250 $ 1,895,704 $ 435,490
Operating expenses:        
Research and development 3,479,776 2,151,932 6,352,726 3,964,833
General and administrative 1,361,166 1,582,581 3,141,505 3,109,596
Change in fair value of contingent consideration 539,980 551,098
Total operating expenses 5,380,922 3,734,513 10,045,329 7,074,429
Loss from operations (4,237,745) (3,323,263) (8,149,625) (6,638,939)
Interest income 44,164 6,466 47,797 11,687
Other (expense) income, net (53,224) 7,716 121,796 77,443
Total non-operating income (expenses), net (9,060) 14,182 169,593 89,130
Net loss (4,246,805) (3,309,081) (7,980,032) (6,549,809)
Net loss - non-controlling interest (196,734) (90,166) (403,195) (140,956)
Net loss attributable to Heat Biologics, Inc. $ (4,050,071) $ (3,218,915) $ (7,576,837) $ (6,408,853)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.27) $ (0.91) $ (0.77) $ (2.06)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted 14,727,682 3,524,483 9,894,367 3,112,412
Other comprehensive loss:        
Net loss $ (4,246,805) $ (3,309,081) $ (7,980,032) $ (6,549,809)
Unrealized gain /(loss) on foreign currency translation 49,946 (9,660) 71,271 (76,035)
Total other comprehensive loss (4,196,859) (3,318,741) (7,908,761) (6,625,844)
Comprehensive loss attributable to non-controlling interest (196,734) (90,166) (403,195) (140,956)
Comprehensive loss $ (4,000,125) $ (3,228,575) $ (7,505,566) $ (6,484,888)

Source